Clinical Trial Update: Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of tacrolimus with immune checkpoint inhibitors nivolumab and ipilimumab in kidney transplant recipients with unresecta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma
• Cutaneous Melanoma
• Cutaneous Squamous Cell Carcinoma
• Merkel Cell Carcinoma

Drugs mentioned

• OPDIVO (nivolumab)
• Prograf (Tacrolimus)
• Yervoy (ipilimumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-06-27